Hood River Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Hood River Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-352,344	Closed	-$29.8M	–	109
2018 Q4	$29.8M	Buy	352,344 +5,929	+2%	+$632K	1.76%	13
2018 Q3	$59.3M	Buy	346,415 +7,938	+2%	+$1.2M	2.62%	4
2018 Q2	$43.7M	Buy	338,477 +47,728	+16%	+$5.33M	2.25%	8
2018 Q1	$30M	Buy	290,749 +5,352	+2%	+$529K	1.68%	17
2017 Q4	$24.4M	Buy	285,397 +20,738	+8%	+$1.8M	1.41%	22
2017 Q3	$22.5M	Buy	264,659 +5,900	+2%	+$467K	1.43%	24
2017 Q2	$19.6M	Buy	258,759 +84,258	+48%	+$5.89M	1.35%	29
2017 Q1	$11.5M	Sell	174,501 -108,393	-38%	-$7.13M	0.86%	47
2016 Q4	$17.9M	Buy	282,894 +31,888	+13%	+$2.01M	1.56%	19
2016 Q3	$16M	Buy	251,006 +181,239	+260%	+$13.3M	1.64%	20
2016 Q2	$5.19M	Buy	+69,767	New	+$5.18M	0.69%	63

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Hood River Capital Management's LGND Position: Q1 2019 in Review

Hood River Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 352,344 shares — an estimated $29.8M sold.

Hood River Capital Management first reported a position in LGND in Q2 2016 and held it in 11 quarters. The position peaked at $59.3M in Q3 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Hood River Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Hood River Capital Management sold 352,344 Ligand Pharmaceuticals shares in Q1 2019, an estimated $29.8M.
Hood River Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2016 and held it in 11 quarters.
Hood River Capital Management's Ligand Pharmaceuticals position peaked at $59.3M in Q3 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Hood River Capital Management's 13F filing for Q1 2019, filed 14 May 2019.